In The News Posted March 5, 2019 Share Posted March 5, 2019 PHILADELPHIA, March 5, 2019 /PRNewswire/ -- Carisma Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on chimeric antigen receptor macrophages, today announced that the Company's management will present... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.